13.03.2013 Views

Faster product registration of medical devices in Japan

Faster product registration of medical devices in Japan

Faster product registration of medical devices in Japan

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

TOCICO 2009 Conference<br />

Myths about <strong>product</strong> <strong>registration</strong> <strong>of</strong><br />

<strong>medical</strong> di l ddevice i i<strong>in</strong> J<strong>Japan</strong><br />

Presented By: Hitoshi Arai, Banyu Pharmaceutical Co., Ltd.<br />

Co Co-workers: workers: Tadashi Ogashiwa, Yuichiro Iwakiri, smith & nephew<br />

orthopedics p K.K.<br />

Date: November 19, 2009<br />

© 2009 TOCICO. All rights reserved.<br />

1


About Hitoshi Arai<br />

• 15 years experience <strong>in</strong> quality<br />

and regulatory compliance <strong>in</strong> the<br />

area <strong>of</strong> <strong>medical</strong> <strong>devices</strong>,<br />

pharmaceuticals and cosmetics<br />

• Has been <strong>in</strong>vestigat<strong>in</strong>g g g how to<br />

apply TOC applications <strong>in</strong><br />

healthcare <strong>in</strong>dustry which is<br />

highly regulated by governmental<br />

bodies.<br />

• Believes Th<strong>in</strong>k<strong>in</strong>g Process and<br />

CCPM would be the most<br />

powerful Kaizen tool to delete<br />

‘T ‘Touch h ti time’ ’ also l <strong>in</strong> i the th regulated l t d<br />

<strong>in</strong>dustry<br />

2<br />

© 2009 TOCICO. All rights reserved.<br />

TOCICO 2009 Conference


Agenda<br />

TOCICO 2009 Conference<br />

1. Environment <strong>of</strong> <strong>Japan</strong>ese <strong>medical</strong> device <strong>in</strong>dustry<br />

2. Common issues among companies<br />

3. An example <strong>of</strong> solution for shorten<strong>in</strong>g regulatory<br />

<strong>registration</strong> lead-time us<strong>in</strong>g Th<strong>in</strong>k<strong>in</strong>g Process (TP)<br />

and CCPM<br />

Note: This presentation is to share my experience at smith & nephew orthopedics<br />

and has noth<strong>in</strong>g to do with Merck & Co., Inc. and/or MSD<br />

3<br />

© 2009 TOCICO. All rights reserved.


Environment <strong>of</strong> <strong>Japan</strong>ese <strong>medical</strong><br />

device <strong>in</strong>dustry(1/6) y( )<br />

Key po<strong>in</strong>ts:<br />

TOCICO 2009 Conference<br />

1. <strong>Japan</strong> is the second biggest market <strong>in</strong> the world.<br />

2. It takes longer time <strong>in</strong> <strong>Japan</strong> than <strong>in</strong> other markets<br />

to get an approval <strong>of</strong> a <strong>medical</strong> device<br />

3. It <strong>of</strong>ten requires more resources <strong>in</strong> <strong>Japan</strong> than <strong>in</strong><br />

other countries co ntries to market a prod <strong>product</strong> ct ddue e to<br />

regulations.<br />

4<br />

© 2009 TOCICO. All rights reserved.


Environment <strong>of</strong> <strong>Japan</strong>ese <strong>medical</strong><br />

device <strong>in</strong>dustry(2/6) y( )<br />

TOCICO 2009 Conference<br />

Total population and its high ag<strong>in</strong>g rate make <strong>Japan</strong> attractive<br />

to <strong>medical</strong> device companies<br />

Data <strong>in</strong> 2007 <strong>Japan</strong> U.K. France Germany<br />

Total population<br />

(Thousands)<br />

Population<br />

ag<strong>in</strong>g rate (%)<br />

127 127,770 770 60 60,975 975 61 61,707 707 82 82,247 247<br />

21.5 16.0 16.5 19.9<br />

Source : AMDD survey issued <strong>in</strong> July 2009.<br />

•AMDD: American Medical Devices and Diagnostics Manufacturers' Association<br />

•Ag<strong>in</strong>g population rate: Ration <strong>of</strong> people who is 65 years old above<br />

5<br />

© 2009 TOCICO. All rights reserved.


Environment <strong>of</strong> <strong>Japan</strong>ese <strong>medical</strong><br />

device <strong>in</strong>dustry(3/6) y( )<br />

TOCICO 2009 Conference<br />

Costs for <strong>registration</strong> related area <strong>in</strong> <strong>Japan</strong> is 17 times higher than E.U.<br />

For Orthopedics <strong>Japan</strong> E.U.<br />

R&D + manufactur<strong>in</strong>g f t i 407 411<br />

Cl<strong>in</strong>ical Trial,<br />

Regulatory and<br />

QQuality lit<br />

106 6<br />

Sales & Market<strong>in</strong>g 3960 1645<br />

WWarehouse h and d<br />

Distribution<br />

652 165<br />

Total 5125 2227<br />

Source : AMDD survey issued <strong>in</strong> July 2009.<br />

*AMDD: American Medical Devices and Diagnostics Manufacturers' Association<br />

*Score 100: R&D ( Before cl<strong>in</strong>ical trial) cost per a device <strong>in</strong> each marketplace<br />

6<br />

© 2009 TOCICO. All rights reserved.


Environment <strong>of</strong> <strong>Japan</strong>ese <strong>medical</strong><br />

device <strong>in</strong>dustry(4/6) y( )<br />

TOCICO 2009 Conference<br />

Average review period <strong>in</strong> <strong>Japan</strong> is longer than <strong>in</strong> other markets.<br />

PTCA balloon and stent<br />

pacemaker<br />

Source : AMDD survey issued <strong>in</strong> July 2009.<br />

*AMDD: American Medical Devices and Diagnostics Manufacturers' Association<br />

7<br />

© 2009 TOCICO. All rights reserved.


Environment <strong>of</strong> <strong>Japan</strong>ese <strong>medical</strong><br />

device <strong>in</strong>dustry(5/6) y( )<br />

TOCICO 2009 Conference<br />

Number <strong>of</strong> employees per dollar sales <strong>in</strong> <strong>Japan</strong> is larger because…<br />

(<strong>Japan</strong> as 100)<br />

• 13 times more employees <strong>in</strong> quality<br />

• 3 times more employees <strong>in</strong> <strong>registration</strong><br />

• Other regulatory g y<br />

affairs<br />

Source : AMDD survey issued <strong>in</strong> July 2009.<br />

*AMDD: American Medical Devices and Diagnostics Manufacturers' Association<br />

8<br />

© 2009 TOCICO. All rights reserved.


M1<br />

Environment <strong>of</strong> <strong>Japan</strong>ese <strong>medical</strong><br />

device <strong>in</strong>dustry(6/6) y( )<br />

TOCICO 2009 Conference<br />

Summary<br />

1. <strong>Japan</strong> is an attractive market for <strong>medical</strong><br />

device companies, however…<br />

22. Need longer period to launch a new <strong>product</strong><br />

3. Need a lot <strong>of</strong> resources to market a <strong>product</strong><br />

It is commonly believed that these are ma<strong>in</strong>ly<br />

due to regulations.<br />

9<br />

© 2009 TOCICO. All rights reserved.


Slide 9<br />

M1<br />

araihit, 8/31/2009


Common issues among companies(1/4)<br />

R&D<br />

Manufactur<strong>in</strong>g<br />

Registration?<br />

Sales & market<strong>in</strong>g<br />

10<br />

Distribution<br />

© 2009 TOCICO. All rights reserved.<br />

TOCICO 2009 Conference<br />

QC/QA<br />

Registration is believed to be one <strong>of</strong> the biggest constra<strong>in</strong>ts to expand<br />

bus<strong>in</strong>ess. Is this true?


Common issues among companies(2/4)<br />

Launch a new<br />

<strong>product</strong> p<br />

OObta<strong>in</strong><br />

an approval <strong>of</strong><br />

a <strong>product</strong><br />

Increase sales now<br />

and <strong>in</strong> the future<br />

TOCICO 2009 Conference<br />

Assumption:<br />

We are not able to improve our sales because we<br />

cannot get an approval <strong>of</strong> a <strong>product</strong> <strong>in</strong> a timely<br />

manner. Is this true?<br />

11<br />

© 2009 TOCICO. All rights reserved.


Common issues among companies(3/4)<br />

Get an approval faster<br />

Hire good Need more Need<br />

experts people de-regulation<br />

TOCICO 2009 Conference<br />

Assumption:<br />

1. If we could hire many experts <strong>in</strong> RA, we would get approvals faster than<br />

<strong>in</strong> the past. Is this true? And is it good enough??<br />

2. Need de-regulation. But is it realistic to expect that government change<br />

the rules for <strong>medical</strong> device companies?<br />

If it happens, can we sell <strong>product</strong>s much better than competitors?<br />

12<br />

© 2009 TOCICO. All rights reserved.


Common issues among companies(4/4)<br />

TOCICO 2009 Conference<br />

Summary:<br />

1. Registration is believed to be one <strong>of</strong> the biggest constra<strong>in</strong>ts<br />

to improve top-l<strong>in</strong>e sales.<br />

2. It is believed many experienced RA people are essential to<br />

get faster approvals. The cost will be very expensive.<br />

3. Hopes de-regulation happens <strong>in</strong> the future…and believes<br />

there is noth<strong>in</strong>g to shorten the lead-time at our end now.<br />

Because review<strong>in</strong>g process is out <strong>of</strong> our control<br />

13<br />

© 2009 TOCICO. All rights reserved.<br />

De-regulation may be effective.<br />

But it does not necessary mean that<br />

we can beat our competitors<br />

competitors.<br />

Because the same rule is applied to all<br />

companies <strong>in</strong>clud<strong>in</strong>g ours now and<br />

<strong>in</strong> the future.


An example <strong>of</strong> solution us<strong>in</strong>g Th<strong>in</strong>k<strong>in</strong>g<br />

Process and CCPM(1/11 )<br />

The organization I took over the responsibility<br />

TOCICO 2009 Conference<br />

• Expertise; The head <strong>of</strong> RAQA was not an RA expert<br />

(that’s me!) and not everyone was <strong>registration</strong> expert<br />

• Operational Efficiency; Had to meet aggressive<br />

operational efficiency targets to generate cost<br />

sav<strong>in</strong>gs (e.g. headcount reductions, etc.) without<br />

hav<strong>in</strong>g an impact to <strong>product</strong> quality<br />

• Had to fully comply with current and future<br />

regulations and submit applications for new<br />

<strong>product</strong>s d t <strong>registration</strong>. i t ti<br />

Mutual distrust among departments<br />

14<br />

© 2009 TOCICO. All rights reserved.


An example <strong>of</strong> solution us<strong>in</strong>g Th<strong>in</strong>k<strong>in</strong>g<br />

Process and CCPM(2/11)<br />

TOCICO 2009 Conference<br />

It was <strong>of</strong>ten highly controversial whether a <strong>product</strong> would require an approval<br />

process or just a notification one<br />

Approval Notification<br />

Implants<br />

Instr Instruments ments<br />

•To submit an application pp form • To submit a notification<br />

•A year long review to register • Able to distribute upon<br />

submitt<strong>in</strong>g a notification.<br />

15<br />

© 2009 TOCICO. All rights reserved.


An example <strong>of</strong> solution us<strong>in</strong>g Th<strong>in</strong>k<strong>in</strong>g<br />

Process and CCPM(3/11)<br />

Intra-company process External process<br />

Create <strong>registration</strong><br />

strategies for <strong>product</strong>s<br />

Documentation work:<br />

Gather <strong>in</strong>formation, craft<br />

application and conduct<br />

test<strong>in</strong>g if necessary<br />

Translation Q&A, discussion<br />

EtoJ E to J Intra Intra-company company<br />

TOCICO 2009 Conference<br />

Presentation<br />

Q&A with<br />

reviewers X3<br />

Expert Committee<br />

Q&A<br />

Approval<br />

F<strong>in</strong>alization, document<br />

check h k and d submission b i i<br />

RReimbursement i b t<br />

16<br />

© 2009 TOCICO. All rights reserved.


An example <strong>of</strong> solution us<strong>in</strong>g Th<strong>in</strong>k<strong>in</strong>g<br />

Process and CCPM(4/11 ( )<br />

TOCICO 2009 Conference<br />

QQuestion1: ti 1<br />

Can we f<strong>in</strong>d hidden buffers <strong>in</strong> the process?<br />

- How and what we should do to encourage people br<strong>in</strong>g<br />

buffers they have?<br />

17<br />

© 2009 TOCICO. All rights reserved.


An example <strong>of</strong> solution us<strong>in</strong>g Th<strong>in</strong>k<strong>in</strong>g<br />

Process and CCPM(5/11)<br />

TOCICO 2009 Conference<br />

RA experts usually never show their buffers concealed beneath<br />

RA is a department<br />

that is <strong>in</strong> charge <strong>of</strong><br />

<strong>registration</strong><br />

Target launch tim<strong>in</strong>g<br />

can be changed by<br />

<strong>in</strong>ternal and external<br />

reasons<br />

RA is blamed by Sales<br />

& Market<strong>in</strong>g<br />

Delay <strong>of</strong> <strong>product</strong> launch<br />

is used as the easiest excuse<br />

for not achiev<strong>in</strong>g a sales target<br />

Sales & Market<strong>in</strong>g are<br />

evaluated their performance<br />

by top-l<strong>in</strong>e sales<br />

18<br />

© 2009 TOCICO. All rights reserved.<br />

Sales prospects<br />

Oft Often tend t d to t be b<br />

Too optimistic


An example <strong>of</strong> solution us<strong>in</strong>g Th<strong>in</strong>k<strong>in</strong>g<br />

Process and CCPM(6/11 )<br />

TOCICO 2009 Conference<br />

RA experts usually never show their buffers concealed beneath<br />

People believes a long review<br />

period is only due to governmental body<br />

A longer review period<br />

<strong>of</strong> <strong>registration</strong> <strong>in</strong> <strong>Japan</strong><br />

is well-known<br />

RA is blamed by<br />

Sales & Market<strong>in</strong>g<br />

Hidden buffers<br />

are <strong>in</strong>visible<br />

to other departments<br />

RA usually places<br />

buffers<br />

<strong>in</strong>side their process<br />

19<br />

© 2009 TOCICO. All rights reserved.<br />

RA work seems to be<br />

very complicated<br />

to other departments


An example <strong>of</strong> solution us<strong>in</strong>g Th<strong>in</strong>k<strong>in</strong>g<br />

Process and CCPM(7/11)<br />

Question2:<br />

Shouldn’t we focus on what we can control?<br />

TOCICO 2009 Conference<br />

• LLead d time ti = Review<strong>in</strong>g R i i time ti (a ( year) ) + Preparation<br />

P ti<br />

• Preparation = Mak<strong>in</strong>g strategy + Gather<strong>in</strong>g<br />

<strong>in</strong>formation + Documentation + Translation (English<br />

to <strong>Japan</strong>ese)+ Document quality check<br />

20<br />

© 2009 TOCICO. All rights reserved.


An example <strong>of</strong> solution us<strong>in</strong>g Th<strong>in</strong>k<strong>in</strong>g<br />

Process and CCPM(8/11)<br />

TOCICO 2009 Conference<br />

1. Holistic th<strong>in</strong>k<strong>in</strong>g: how do we see buffers <strong>in</strong> the process →TOC education<br />

2. Change g the rules:<br />

- Do not blame anyone if a project delays. Never allow to blame <strong>in</strong>dividuals.<br />

- Do not count <strong>product</strong>s which are under pre-review by government<br />

on sales forecast.<br />

SABA (safety buffers) Park<strong>in</strong>son’s law Unreported early completion<br />

Student syndrome Multi-task<strong>in</strong>g Network structure<br />

21<br />

© 2009 TOCICO. All rights reserved.


An example <strong>of</strong> solution us<strong>in</strong>g Th<strong>in</strong>k<strong>in</strong>g<br />

Process and CCPM(9/11)<br />

TOCICO 2009 Conference<br />

Answer:<br />

RReceived i d 88 <strong>of</strong> f examples l th that t relates l t tto th the aforementioned<br />

f ti d<br />

six items that affect the process <strong>of</strong> a project<br />

22<br />

© 2009 TOCICO. All rights reserved.


An example <strong>of</strong> solution us<strong>in</strong>g Th<strong>in</strong>k<strong>in</strong>g<br />

Process and CCPM(10/11)<br />

• Now we can see SABAs(Buffers) <strong>in</strong> the process<br />

TOCICO 2009 Conference<br />

• We tried to re align the process us<strong>in</strong>g the concept <strong>of</strong><br />

CCPM<br />

My <strong>in</strong>itial sketch<br />

23<br />

© 2009 TOCICO. All rights reserved.<br />

Results <strong>of</strong> team discussion


An example <strong>of</strong> solution us<strong>in</strong>g Th<strong>in</strong>k<strong>in</strong>g<br />

Process and CCPM(11/11 )<br />

TOCICO 2009 Conference<br />

• We brought up this concept at a workshop <strong>of</strong> a s<strong>of</strong>tware<br />

vendor d<br />

Other rules:<br />

-Strategies must be developed by a whole<br />

team to share regulatory knowledge/<br />

expertise<br />

- EEach h process must t owned d by b a person <strong>in</strong> i<br />

charge<br />

24<br />

© 2009 TOCICO. All rights reserved.


Results (1/2)<br />

TOCICO 2009 Conference<br />

• The application <strong>of</strong> CCPM reduced the touch time by 59% <strong>in</strong><br />

theory and 31-69% reduction <strong>in</strong> actual<br />

Former Apply CCPM Actual<br />

Process<br />

YTD<br />

PPreparation ti 6 3 22-6 6<br />

Presentation 1 0.5 0.5<br />

Q&A (1) 3 1 1-3<br />

Q&A (2) 3 1 1<br />

Q&A (3) 3 1 0.5<br />

Total 16 6.5(59%) 5-11(31-69%)<br />

* Exclud<strong>in</strong>g 1 year standard review time by governmental body<br />

25<br />

© 2009 TOCICO. All rights reserved.


Results (2/2)<br />

Number <strong>of</strong> submission<br />

& approvals pp<br />

TOCICO 2009 Conference<br />

Multi-projects No head-count <strong>in</strong>crease<br />

• Before implementation <strong>of</strong> TP and CCPM, only one application for a new<br />

<strong>product</strong> was submitted <strong>in</strong> 2006. The number became four <strong>in</strong> 2007 and six<br />

<strong>in</strong> 2008, 2008 respectively<br />

respectively.<br />

• RA team was not able to carry out other regulatory projects <strong>in</strong> 2006 than<br />

a new <strong>product</strong> <strong>registration</strong>. However, the team has been manag<strong>in</strong>g all the<br />

projects p j above s<strong>in</strong>ce 2007 and f<strong>in</strong>ished them all now without any y<br />

headcount <strong>in</strong>crease s<strong>in</strong>ce 2006.<br />

26<br />

© 2009 TOCICO. All rights reserved.


Summary<br />

TOCICO 2009 Conference<br />

• Th<strong>in</strong>k<strong>in</strong>g Process and CCPM are the one <strong>of</strong> the most powerful<br />

tool to shorten <strong>registration</strong> lead-time. Because a lot <strong>of</strong> time is<br />

used not only by governmental reviewers, but also by applicants<br />

<strong>in</strong> preparation and Q&A process.<br />

• By putt<strong>in</strong>g wisdom <strong>of</strong> experts <strong>in</strong>to strategy mak<strong>in</strong>g process, we<br />

can operate multiple projects with less number <strong>of</strong> people with<br />

less expertise. p Each <strong>in</strong>dividuals has been grow<strong>in</strong>g g g through g these<br />

projects.<br />

• It is said that the constra<strong>in</strong>t <strong>of</strong> sales <strong>in</strong>crease was regulatory<br />

process. Now the company changed its idea, the constra<strong>in</strong>ts is <strong>in</strong><br />

sales l & market<strong>in</strong>g k ti and d try t to t use TP to t review i their th i sales l<br />

27<br />

© 2009 TOCICO. All rights reserved.


Thank you for your attention and also<br />

thanks to to the the great great RA/QA RA/QA team<br />

team<br />

TOCICO 2009 Conference<br />

28<br />

© 2009 TOCICO. All rights reserved.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!